Topics

PubMed Journals Articles About "Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply" RSS

13:20 EDT 5th April 2020 | BioPortfolio

Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply articles that have been published worldwide.

More Information about "Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply" on BioPortfolio

We have published hundreds of Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply news stories on BioPortfolio along with dozens of Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply Clinical Trials and PubMed Articles about Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply Companies in our database. You can also find out about relevant Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply Drugs and Medications on this site too.

Showing "Early Delayed Cardioversion Recent Onset Atrial Fibrillation Reply" PubMed Articles 1–25 of 23,000+

Early or delayed cardioversion in atrial fibrillation?

Atrial fibrillation is one of the most common arrhythmias. As the symptoms can be abrupt in onset it is associated with a substantial burden on the medical emergency system. By routine practice patients with symptomatic atrial fibrillation of a duration less than 48 hours are commonly offered cardioversion therapy. Data from a recent study shows that more than two thirds of patients convert to sinus rhythm spontaneously within 48 hours. A watch-and-wait approach in rhythm control management may be suggested...


Is delayed cardioversion the better approach in recent-onset atrial fibrillation? Yes.

Atrial fibrillation is the most common sustained arrhythmia encountered in primary care practice and represents a significant burden on the health care system with a higher than expected hospitalization rate from the emergency department. The first goal of therapy is to assess the patient's symptoms and hemodynamic status. There are multiple acute management strategies for atrial fibrillation including heart rate control, immediate direct-current cardioversion, or pharmacologic cardioversion. Given the vari...

Pharmacologic cardioversion of recent-onset atrial fibrillation: a systematic review and network meta-analysis.

We sought to identify the most effective antidysrhythmic drug for pharmacologic cardioversion of recent-onset atrial fibrillation (AF).


Comparing TEE vs Non-TEE guided cardioversion of atrial fibrillation: the ENSURE-AF trial.

ENSURE-AF (NCT02072434) assessed therapy with edoxaban versus enoxaparin-warfarin in patients with nonvalvular atrial fibrillation (AF) undergoing elective electrical cardioversion (ECV).

Mechanical atrial recovery after cardioversion in persistent atrial fibrillation evaluated by bidimensional speckle tracking echocardiography.

Atrial fibrillation induces reversible electrical and mechanical modifications (atrial remodeling). Atrial stunning is a mechanical dysfunction with preserved bioelectrical function, occurring after successful atrial fibrillation electrical cardioversion (ECV). Two-dimensional speckle tracking echocardiography is a new technology for evaluating atrial mechanical function. We assessed atrial mechanical function after ECV with serial two-dimensional speckle tracking echocardiography evaluations. The investiga...

Protocol for a systematic review and network meta-analysis of the management of new onset atrial fibrillation in critically unwell adult patients.

New onset atrial fibrillation is the most commonly encountered arrhythmia in critically unwell patients with a reported incidence of 4% to 29%. The occurrence of new onset atrial fibrillation may precipitate acute heart failure and lead to thromboembolic complications as well as being associated with increased in-hospital and in intensive care unit (ICU) mortality. Despite being common, much of our current knowledge regarding the treatment of new onset atrial fibrillation comes from patients with chronic at...

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.

Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent recurrence. This is an update of a review previously published in 2006, 2012 and 2015.

Efficacy and Safety of Outpatient Clinic-based Elective External Electrical Cardioversion in Patients with Atrial Fibrillation.

Little is known about the outcomes of outpatient clinic-based elective external cardioversion (OPC-ECV) for persistent atrial fibrillation (PeAF). We investigated the acute, short-term, and long-term elective external cardioversion (ECV) outcomes.

Chemical Cardioversion of Atrial Flutter and Fibrillation in the Pediatric Population with Ibutilide.

Atrial flutter (AFL) and atrial fibrillation (AF) are common in pediatric patients with congenital heart disease (CHD) and structurally normal hearts as well. Chemical cardioversion is attractive for patients with AFL/AF for a short period of time because of the ability to avoid sedation. We review a single center's experience with Ibutilide in pediatric patients in an effort to report on its safety and efficacy.

Potassium infusion increases the likelihood of conversion of recent-onset atrial fibrillation-A single-blinded, randomized clinical trial.

The optimal antiarrhythmic management of recent-onset atrial fibrillation (ROAF) or atrial flutter is controversial and there is a considerable variability in clinical treatment strategies. It is not known if potassium infusion has the potential to convert ROAF or atrial flutter to sinus rhythm (SR). Therefore, we aimed to investigate if patients with ROAF or atrial flutter and plasma-potassium levels ≤4.0 mmol/L have increased probability to convert to SR if the plasma-potassium level is increased toward...

Tissue Doppler-derived atrial dyssynchrony predicts new-onset atrial fibrillation during hospitalization for ST-elevation myocardial infarction.

Atrial dyssynchrony, but not atrial enlargement/dysfunction, reflects acute atrial histopathological changes. It has been shown to be associated with new-onset atrial fibrillation (NOAF) in various clinical conditions but was not studied in the acute phase of ST-elevation myocardial infarction (STEMI) which is the aim of the current study.

Hot off the Press: Chemical vs. Electrical Cardioversion for Atrial Fibrillation.

Atrial Fibrillation (AF) is a significant dysrhythmia that often requires treatment in the emergency department (ED). This can be performed with rhythm control using electrical or chemical cardioversion, or with rate control. There is widespread variation in management of AF within Canada and worldwide. This study focuses on rhythm control techniques, comparing emergency department length of stay when using an electrical-first strategy versus a chemical-first strategy of cardioversion.

Left atrial mechanical remodelling assessed as the velocity of left atrium appendage wall motion during atrial fibrillation is associated with maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation.

The velocity of left atrium appendage (LAA) wall motion during atrial fibrillation (AF) is a potential marker of mechanical remodelling. In this study, we investigated whether the velocity of LAA wall motion during AF predicted the success of electrical cardioversion and long-term sinus rhythm maintenance. Standard echocardiographic data were obtained by transthoracic echocardiography, and LAA wall motion velocities were measured by transoesophageal echocardiography. With logistic regression and receiver op...

Atrial fibrillation and stroke: how much atrial fibrillation is enough to cause a stroke?

The association between atrial fibrillation and stroke is firmly established, and anticoagulation reduces stroke risk in patients with atrial fibrillation. However, the role of anticoagulation in very brief durations of atrial fibrillation (subclinical atrial fibrillation) is an area of controversy.

Correlation between atrial premature depolarisations after electrical cardioversion and risk for atrial fibrillation recurrence in horses.

Cardioversion efficacy of nifekalan in patients with sustained atrial fibrillation after radiofrequency ablation.

To evaluate the efficacy and safety of nifekalan (NIF) on cardioversion in atrial fibrillation (AF) patients post radiofrequency ablation, and investigate the relevant factors related to the cardioversion efficacy of NIF. We screened patients with sustained AF rhythm after radiofrequency ablation between November 2016 and July 2018. Participants were treated with intravenous NIF 0.4 mg/kg within 5-10 minutes after ablation. We observed the adverse reaction, and monitored the rhythm, heart rate, QT interval...

New-Onset Atrial Fibrillation in St-Segment Elevation Myocardial Infarction: Predictors and Impact on Therapy And Mortality.

New-onset atrial fibrillation complicating acute myocardial infarction represents an important challenge, with prognostic significance.

Early recurrence of atrial tachyarrhythmia during the 90-day blanking period after cryoballoon ablation in patients with atrial fibrillation: The characteristics and predictive value of early recurrence on long-term outcomes.

To investigate the characteristics of early recurrence (ER) of atrial tachyarrhythmia (ATA) defined as atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) during a 90-day blanking period after pulmonary vein isolation by cryoablation (PVI-C) in patients with symptomatic drug refractory AF. Specifically, to determine if ER of ATA during the blanking period can predict late recurrence (LR) during a 12-month follow-up period.

Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death.

Catheter ablation for atrial fibrillation (CAF) improves symptoms, but whether CAF improves outcome is less clear. The purpose of this study was to investigate whether CAF is associated with improved outcome in atrial fibrillation (AF) patients with previous direct current (DC) cardioversion.

Low serum albumin levels and new-onset atrial fibrillation in the ICU: a prospective cohort study.

The aim was to determine if a low serum albumin (SA) level was associated with the occurrence of new onset atrial fibrillation (NOAF) during the first 48 h of intensive care unit (ICU) admission.

Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter.

Atrial arrhythmias commonly occur in patients with cardiac amyloidosis (CA), but there is limited data on safety or efficacy of cardioversion (DCCV) for management of these rhythms in CA. We identified 25 patients with CA (20 with transthyretin (TTR) and 5 with light-chain (AL) amyloidosis) at Duke University who underwent DCCV for atrial arrhythmias and documented procedural success, complications, and long-term morbidity and mortality. While DCCV successfully restored sinus rhythm in 96% of patients, 36% ...

Risks and management of cardioversion and catheter ablation in atrial fibrillation.

Improved brain perfusion after electrical cardioversion of atrial fibrillation.

Atrial fibrillation (AF) has been associated with reduced brain volume, cognitive impairment, and reduced cerebral blood flow. The causes of reduced cerebral blood flow in AF are unknown, but no reduction was seen in individuals without the arrhythmia in a previous study. The aim of this study was to test the hypothesis that brain perfusion, measured with magnetic resonance imaging (MRI), improves after cardioversion of AF to sinus rhythm (SR).

Atrial Fibrillation and Preexcitation - A Licence to Kill.

Atrial fibrillation becomes a potentially lethal arrhythmia in the presence of preexcitation because the rapid ventricular activation can result in ventricular fibrillation. Fortunately, radiofrequency ablation is an effective treatment for these patients. Specific points of interest regarding this association are the mechanism of increased incidence of atrial fibrillation and the current management of patients presenting in atrial fibrillation. These are discussed in this editorial.

Putative role of Brugada syndrome genes in familial atrial fibrillation.

Familial atrial fibrillation (FAF), a not uncommon arrhythmia of the atrium, is characterized by heritability, early onset and absence of other heart defects. The molecular and genetic basis is still not completely clear and genetic diagnosis cannot be achieved in about 90% of patients. In this study, we present the results of genetic screening by next generation sequencing in affected Russian families.


Quick Search